December #184 : The POZ 100-Cure All Glossary

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


The POZ 100-Accelerating the End of AIDS

The POZ 100-The Seekers

The POZ 100-The Hunters

The POZ 100-The Defenders

The POZ 100-The Soldiers

The POZ 100-Cure All Glossary

Love is the Cure

From the Editor

More Than a Feeling


Letters-December 2012


Towards an HIV Cure

POZ Planet

A Very Big Kiki

Russians Deploy 'Google Bombs'

Home Alone

Say What-Paris Hilton

Back to School

What's a Buyers' Club? Matthew Knows.

iPad Video Game to Teach HIV Prevention Skills


Tried and True

Care and Treatment

One a Day to Keep Heart Attacks Away?

One Form to Rule Them All

Stribild is Here


Nature's Little Helpers

GMHC Treatment Issues December 2012

Research Notes

Prevention: Selzentry Is PrEP Contender

Treatment: Dolutegravir Shows Promise

Cure: Curious Cohort on Early Treatment

Concerns: Fewer Comebacks From Heart Attacks

POZ Survey Says

Healthy Technology

POZ Heroes

Breaking Bad Cycles

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2012

The POZ 100-Cure All Glossary

A glossary of need-to-know cure terminology

Berlin Patient
His name is Timothy Brown, and he is the first person to be cured of HIV. After being diagnosed with leukemia, he received chemotherapy and radiation to wipe out his immune system, which was reseeded with stem cells from a donor whose CD4 cells lacked the CCR5 receptor HIV needs to infect them (the donor inherited the genetic trait from both parents). Years later, no HIV capable of reproducing has been found in Brown’s body, and he remains off ARVs. Duplicating these results, using adult (and umbilical cord blood) donations and genetically modified stem cells—and without needing the lethal chemo and radiation—is a cure research priority.

To infect a CD4 cell, HIV must attach to two of its three receptors. HIV always uses the main CD4 receptor, which we all have. HIV also needs either the CCR5 or CXCR4 receptor. The most common form of HIV targets CCR5, particularly in the early years of infection. HIV med Selzentry (maraviroc) blocks this receptor. Finding ways to knock out CCR5, which serves no important purpose in the body, is a major goal of cure scientists.  

Using drugs to turn on inactive HIV-infected CD4 cells (see HIV Reservoir below) can actually make people very ill. Instead, researchers are looking at the cellular proteins that keep HIV tucked away in these cells: histone deacetylases, or HDACs, being one group in particular. The cancer drug Zolinza (vorinostat) and the alcohol dependency drug Antabuse (disulfiram) are two very different drugs with one thing in common—they inhibit HDACs.  

HIV Reservoir
Current antiretroviral therapy is good at preventing CD4 cells from becoming infected and at blocking “active” infected cells from producing new HIV. However it’s not good against inactive, or latent, CD4 cells that harbor the virus; if they’re not active—and many lie dormant for decades—ARV meds can’t get at the virus. Cure researchers are determined to find ways to purge HIV from this reservoir.

Also know as IL-7, it is a synthetic version of a naturally occurring messenger hormone. It’s being studied for its ability to prompt CD4 cell reservoirs to give up their HIV cargo without activating the immune system and making it go haywire.

“RNA interference” began when researchers found they could insert genetic fragments to “silence” the genes in petunias responsible for giving them their purple color. This technique is now being studied in a variety of diseases, including HIV, as a way to block the genes that stand in the way of a cure.

Zinc Finger Nucleases
Also know as ZFNs, they are molecular scissors that can slice genes, rendering them useless. Sangamo BioSciences is experimenting with ZFNs as a way to clip genes that produce CCR5 receptors on CD4 cells. It’s also looking at using ZFNs to render the gene dysfunctional in bone marrow cells, which can be used to regrow immune systems that contain CCR5-free CD4s.

Introduction | The Seekers | The Hunters | The Defenders | The Soldiers | Cure-All Glossary |

To read the 2011 POZ 100, click here.
To read the 2010 POZ 100, click here.

Search: Berlin Patient, CCR5, HDACs, HIV Reservoir, Interleukin-7, RNAi, Zinc Finger Nucleases

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.